Delays in clinical trials is one of the several challenges that the pharmaceutical and healthcare industry faced following the Covid-19 pandemic.

GlobalData conducted a survey to identify the primary clinical trial concerns across North America, Europe, Asia Pacific (APAC) and Rest of World (RoW).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Covid-19-related clinical trial disruptions emerge as primary concern across all regionsPrimary Clinical Trial Concerns Related to the COVID-19 Outbreak by Geography 

An assessment of the survey results found that the inability to start or delays in clinical trials were the main concerns for the companies across all four regions.​

Such concerns were the highest in APAC (33%) and RoW (33%) regions, followed by North America (29%) and Europe (29%).

The concerns regarding the impact on clinical trial participants were also highest in the APAC region (31%). The figure stands at 29% in RoW, 25% in North America and 24% in Europe.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In North America, 29% of the respondents were most worried about the safety of the patients recruited for the trials amid Covid-19 outbreak. Similar views were shared by 22% in Europe, 17% in APAC and 13% in RoW.

Negative impact of agency submissions was a higher concern in Europe (13%) and the RoW (13%), than in APAC (10%) and North America (9%).

The percentage of respondents that considered loss of investment as the primary concern was the highest in Europe (10%), followed by North America (7%), APAC (4%) and RoW (4%).

Around 8% of the respondents in RoW region highlighted other concerns. The figure drops to 4% in APAC and 1% each in North America and Europe.

The analysis is based on responses received for the ‘Coronavirus Survey – COVID-19 and Decentralised Clinical Trials’ conducted by GlobalData between 04 June and 22 June 2020.